Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Resisting Calls For More Freedom To Produce Generics For Export, Australia's IP Regime Is Safe For Now, But Generic Makers, Unions Ready For Battle

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - An earlier proposal put forth to legislators by generics maker Hospira to ease restrictions on producing generics for export has been shot down

You may also be interested in...



An Unexpected Foe Challenges Pharma In Aussie Generics-For-Export Battle

Generic manufacturers and labor groups in Australia say current patent legislation is handicapping industry's ability to compete on the world stage and that, if the status quo remains, manufacturing and jobs are likely to go elsewhere

Australia Department Of Innovation Releases 10-Year Plan On Pharma Strategy

PERTH, Australia - Australia's Minister for Innovation, Industry, Science and Research, Senator Kim Carr, has released a sweeping report that outlines a 10-year plan for the country's pharmaceutical and biotech industry

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel